Jun 09, 2021 / 12:50PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD
Great. Good morning, everybody. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs, and we're very pleased to be hosting Eli Lilly today at our virtual healthcare conference.
Joining us today from the company, we have Anne White, who is President of Lilly Oncology; and Jake Van Naarden, who is CEO of Loxo Oncology at Lilly. Thank you both so much for joining us today. Really appreciate the time.
Questions and Answers:
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MDAs I know it's an extremely busy time of the year. You're post the ASCO Conference. Maybe to start, I thought a good place would be just to give us an overview of kind of the company's current strategy here in oncology.
What's differentiated about your approach versus other players? And then how are you thinking about the different verticals, targeted oncology versus IO, as obviously there's a lot of ongoing efforts there at the company.
Jacob S. Van Naarden<
Trustpilot
